About Agendia
Agendia is a Healthcare company based in Irvine (United States) founded in 2003 by Laura van 't Veer. Genomic diagnostic products for cancer treatment are provided. Agendia has raised $123 million across 7 funding rounds from investors including ING, Debiopharm and European Union. Agendia offers products and services including MammaPrint and BluePrint. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is AGENDIA, INC. Its competitors include Guardant Health, Foundation Medicine and ArcherDX; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2003 and based in Irvine, United States, genomic diagnostic products for oncology are developed and supplied by Agendia. Breast cancer and solid tumors are analyzed through the flagship MammaPrint test. Tumor genes are subtyped into Luminal, HER2, and Basal categories via the BluePrint molecular test. Clinical trials in oncology are supported by the FLEX platform and I-SPY2 initiative.
- Total Equity Funding$123M (USD)
in 7 rounds
- Latest Funding Round$4.7M (USD), Grant
Dec 2018
- InvestorsING
& 10 more
Products & Services of Agendia
Agendia offers a comprehensive portfolio of products and services, including MammaPrint and BluePrint.
Assesses breast cancer recurrence risk using genomic analysis.
Determines molecular subtyping of breast cancer tumors for treatment guidance.
Apps and channels of Agendia
its YouTube channel Agendia Inc has 321 subscribers and 30 videos.
Videos from Agendia
The most watched videos on Agendia's YouTube channel, Agendia Inc (321 subscribers). Click a video to play it here.
More on Agendia Inc.
Funding Insights of Agendia
Agendia has successfully raised a total of $123M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $4.7 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $123M
- Total Rounds 7
- Last Round Grant — $4.7M
- Investors Count 11
All 7 funding rounds of Agendia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2018 | $4.7M | Grant | – | – | |
| Jul 2018 | $35M | Series F | – | Athyrium Capital Management | – |
| Oct 2015 | $1.01M | Grant | – | – | |
| Jul 2015 | $4.5M | Grant | – | – | |
| May 2012 | $65M | Series F | – | Debiopharm | |
| Sep 2009 | $23M | Series E | – | ING | |
| Dec 2005 | Series A | – | AXA Investment Managers, Global Life Science Ventures | – |
11 investors in total: 11 institutional.
Investors in Agendia
Agendia has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include ING, Debiopharm and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity investments are managed by the firm. | athyrium.com | New York, United States | ||
Private equity and venture captial firm focused on healthcare sectors | gildehealthcare.com | Cambridge, United States | ||
Life-Sciences & Offline focused VC firm funding companies in Netherlands | vanherkgroep.nl | Rotterdam, Netherlands | ||
Sustainable investing in conscious consumer, energy transition, and healthy living sectors. | 2011 | korys.be | ||
Early & late stage life sciences focused VC firm funding companies in the US and Europe | global-life-science-ventures.com | Munich, Germany | ||
Diversified alternative assets are managed through investment strategies. | 1994 | axa-im.com | Puteaux, France | |
Private equity and accelerator investments are directed toward multiple sectors. | riveancapital.com | Brussels, Belgium | ||
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Biopharmaceutical company focused on oncology, infectious diseases, and orphan drugs | 1979 | debiopharm.com | Lausanne, Switzerland |
Investor details for Agendia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Agendia
38 people are tracked at Agendia (18 in leadership, 9 in board & advisors, 11 in team).
| Name | Role | Group |
|---|---|---|
Laura van 't Veer | Co-Founder | Leadership |
Vicky Reyes Huerta | Sr. Global Vice President Of Reimbursement And Government Affairs | Leadership |
Ron Kalfus | CFO | Leadership |
Mark R. Straley | Chief Executive Officer | Leadership |
Kurt Becker | Chief Financial Officer | Leadership |
William Audeh | Chief Medical Officer | Leadership |
Roopom Banerjee | Chief Strategy Officer & Head Of Business Development | Leadership |
Kenyon Sweeney | General Manager, Sales & Marketing | Leadership |
Andrea Menicucci | Vice President Of Clinical Development | Leadership |
Manny Jaime | Sr. Director, Medical Information Systems | Leadership |
Callie Laden | Vice President Of Commercial Operations And Strategic Analytics | Leadership |
Chris Wilson | Director Information Technology | Leadership |
Marion Wasmayr | Director Business Development And Distributors EMEA | Leadership |
René Bernards | Founder And Chief Scientific Officer | Leadership |
Karen Guzdzial | Sr. Director, Healthcare Provider Marketing | Leadership |
Michelle Lanman | Senior Regional Sales Director | Leadership |
Tae Kim | VP Global Finance | Leadership |
Stephen Luke | Region Sales Director - West | Leadership |
David Devigne | Supervisory Board Member | Board & advisors |
François Ferré | Supervisory Board Member | Board & advisors |
18 more people are available in the full profile.
Complete people profiles for Agendia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Agendia
3 dated milestones of Agendia across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Agendia is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $4.7M.
Competitors of Agendia
Agendia has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Foundation Medicine and ArcherDX.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. |
Detailed competitors of Agendia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Agendia
The website of Agendia (agendia.com) receives about 9K visits a month.
- Monthly visits9K
▼ 15.4% vs previous month
Websites whose visitors overlap most with Agendia. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
proteopedia.org | proteopedia.org | 100% | #272,080 | – | |
hcplc.org | hcplc.org | 77% | #247,860 | – | |
breastpath.com | breastpath.com | 42% | – |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Agendia (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Agendia
Complete news archive for Agendia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Agendia
Agendia was founded in 2003 and raised its 1st funding round 2 years after it was founded.
Agendia is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Agendia is a funded company, having raised a total of $123M across 7 funding rounds to date.
Founded in 2003 and based in Irvine, United States, genomic diagnostic products for oncology are developed and supplied by Agendia. Breast cancer and solid tumors are analyzed through the flagship MammaPrint test. Tumor genes are subtyped into Luminal, HER2, and Basal categories via the BluePrint molecular test. Clinical trials in oncology are supported by the FLEX platform and I-SPY2 initiative.
Agendia's top competitors include Guardant Health, Foundation Medicine and ArcherDX.
Agendia offers MammaPrint and BluePrint.
Agendia has 11 investors. Key investors include ING, Debiopharm, European Union, AXA Investment Managers, and Athyrium Capital Management.
Agendia operates through Agendia, Inc..